Steroid differentiation: The safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American ophthalmological society thesis)

Transactions of the American Ophthalmological Society

Volumn 112, Issue , 2014, Pages 116-141

  Kuppermann, Baruch D ^a   Zacharias, Leandro Cabral ^b   Kenney, M Cristina ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; LOTEPREDNOL ETABONATE; METHYLPREDNISOLONE; OXIDOREDUCTASE; TRIAMCINOLONE ACETONIDE; CORTICOSTEROID;

ANIMAL CELL; ARTICLE; CELL DAMAGE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; EMBRYO; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; RAT; RETINA CELL; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; EMBRYONIC STEM CELL; EPITHELIUM CELL; METABOLISM; MITOCHONDRION; PIGMENT EPITHELIUM;

ADRENAL CORTEX HORMONES; CELL SURVIVAL; CELLS, CULTURED; EMBRYONIC STEM CELLS; EPITHELIAL CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; OXIDOREDUCTASES; RETINAL PIGMENT EPITHELIUM;

EID: 84922535250     PISSN: None     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Article

References (145)

1. Leopold IH. Nonsteroidal and steroidal anti-inflammatory agents. In: Sears ML, Tarkkanen A, eds. Surgical Pharmacology of the Eye. New York: Raven Press; 1985.
2. Pagano G, Bruno A, Cavallo-Perin P, Cesco L, Imbimbo B. Glucose intolerance after short-term administration of corticosteroids in healthy subjects. Prednisone, deflazacort, and betamethasone. Arch Intern Med1989;149(5):1098-1101.
3. Saag KG. Glucocorticosteroid-induced osteoporosis. Endocrinol Metab Clin North Am2003;32(1):135-157.
4. Stanbury RM, Graham EM. Systemic corticosteroid therapy—side effects and their management. Br J Ophthalmol1998;82(6):704-708.
5. Weijtens O, van der Sluijs FA, Schoemaker RC, et al. Peribulbar corticosteroid injection: vitreal and serum concentration after dexamethasone disodium phosphate injection. Am J Ophthalmol1997;123(3):358-363.
6. Weijtens O, Schoemaker RC, Cohen AF, et al. Dexamethasone concentration in vitreous and serum after oral administration. Am J Ophthalmol1998;125(5):673-679.
7. Weijtens O, Feron EJ, Schoemaker RC, et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol1999;128(2):192-197.
8. Weijtens O, Schoemaker RC, Romjin FP, Cohen AF, Lentjes EG, van Meurs JC. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology2002;109(10):1887-1891.
9. Herrero-Vanrell R, Cardillo JA, Kuppermann BD. Clinical applications of the sustained-release dexmethasone implant for treatment of macular edema. Clin Ophthalmol2011;5:139-146.
10. Lee HB, Pulido JS, McCannel CA, Buettner H. Role of inflammation in retinal vein occlusion. Can J Ophthalmo. 2007;42:131-133.
11. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol2002;240:782-783.
12. Sivaprasad S, McCluskey P, Lightman S. Intravitreal steroids in the management of macular oedema. Acta Ophthalmol Scand2006;84:722-733.
13. Jonas JB, Kreissig I, Kamppeter B, Degenring RF. Intravitreal triancinolone acetonide for the treatment of intraocular edematous and neovascular diseases. Ophthalmologe2004;101:113-120.
14. Spaide RF. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol2006;141:149-156.
15. Spaide RF. Combination therapies for choroidal neovascularization. In: Holz FG, Spaide RF, eds. Medical Retina (Essentials in Ophthalmology series). Berlin: Springer; 2007:90-104.
16. Citirik M, Dilsiz N, Batman C, Zilelioglu O. Comparative toxicity of 4 commonly used intravitreal corticosteroids on rat retina. Can J Ophthalmol2009;44:e3-8.
17. Glybina IV, Kennedy A, Ashton P, Abrams GW, Iezzi R. Photoreceptor neuroprotection in RCS rats via low-dose intravitreal sustained-delivery of fluocinolone acetonide. Invest Ophthalmol Vis Sci2009;50:4847-4857.
18. Glybina IV, Kennedy A, Ashton P, Abrams GW, Iezzi R. Intravitreous delivery of the corticosteroid fluocinolone acetonide attenuates retinal degeneration in S334ter-4 rats. Invest Ophthalmol Vis Sci2010;51:4243-4252.
19. Naveh N, Weissman C. Prolonged corticosteroid treatment exerts transient inhibitory effect on prostaglandin E2 release from rabbits’ eyes. Prostaglandins Leukot Essent Fatty Acids. 1991;42:101-105.
20. Lewis GD, Campbell WB, Johnson AR. Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells. Endocrinology1986;119:62-69.
21. Heffernan JT, Futterman S, Kalina RE. Dexamethasone inhibition of experimental endothelial cell proliferation in retinal venules. Invest Ophthalmol Vis Sci1978;17:565-568.
22. Bhattacherjee P, Williams RN, Eakins KE. A comparison of the ocular anti-inflammatory activity of steroidal and nonsteroidal compounds in the rat. Invest Ophthalmol Vis Sci1983;24:1143-1146.
23. Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto RC Jr. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem2002;80:667-677.
24. Ando N, Sen HA, Berkowitz BA, Wilson CA, de Juan E Jr. Localization and quantification of blood-retinal barrier breakdown in experimental proliferative vitreoretinopathy. Arch Opthalmol1994;112:117-122.
25. Matsuda S, Gomi F, Oshima Y, Tohyama M, Tano Y. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci2005;46:1062-1068.
26. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol1998;341:309-315.
27. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol2011;152:686-694.
28. Penfold PL, Wen L, Madigan MC, Gillies MC, King NJ, Provis JM. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol2000;121:458-465.
29. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci2005;46:1440-1444.
30. Miyamoto N, Iossifov D, Metge F, Behar-Cohen F. Early effects of intravitreal triamcinolone acetonide on macular edema. Mechanistic implication. Ophthalmology2006;113:2048-2053.
31. Graham RO, Peyman GA. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol1974;92(2):149-154.
32. Peyman GA, Rose M, Sanders D. Intravitreal antibiotic injection and vitrectomy in acute bacterial endophthalmitis. Can J Ophthalmol1976;11:188-190.
33. Peyman GA, Vastine DW, Meisels HI. The experimental and clinical use of intravitreal antibiotics to treat bacterial and fungal endophthalmitis. Doc Ophthalmol1975;39:183-201.
34. Peyman GA, Vastine DW, Diamond JG. Vitrectomy and intraocular gentamicin management of Herellea endophthalmitis after incomplete phacoemulsification. Am J Ophthalmol1975;80:764-765.
35. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc1979;77:171-180.
36. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol1980;89:131-136.
37. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol1980;90:810-816.
38. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol1985;103:708-711.
39. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol1995;23:29-38.
40. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina2000;20:244-250.
41. Shah A, Branley M. Use of intravitreal triamcinolone in the management of birdshot retinochoroidopathy associated with cystoid macular oedema: a case study over a three-year period. Clin Experiment Ophthalmol2005;33:442-444.
42. Karacorlu M, Arf Karacorlu S, Ozdemir H. Intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada syndrome. Eur J Ophthalmol2006;16:481-483.
43. Pathengay A. Intravitreal triamcinolone acetonide in serpiginous choroidopathy. Indian J Ophthalmol2005;53:77-79.
44. Adigüzel U, Sari A, Ozmen C, Oz O. Intravitreal triamcinolone acetonide treatment for serpiginous choroiditis. Ocul Immunol Inflamm2006;14:375-378.
45. Ozdemir H, Karacorlu M, Karacorlu S. Intravitreal triamcinolone acetonide in sympathetic ophthalmia. Graefes Arch Clin Exp Ophthalmol2005;243:734-736.
46. Karacorlu M, Ozdemir H, Karacorlu S. Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema. Acta Ophthalmol Scand2003;81:648-652.
47. Ip M, Kahana A, Altaweel M. Treatment of central retinal vein occlusion with triamcinolone acetonide: an optical coherence tomography study. Semin Ophthalmol2003;18:67-73.
48. Ciardella AP, Klancnik J, Schiff W, Barile G, Langton K, Chang S. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Graefes Arch Clin Exp Ophthalmol2004;242:1024-1027.
49. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology2004;111:218-224.
50. Shields CL, Demirci H, Dai V, et al. Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. Retina2005;25:868-874.
51. Shields CL, Demirci H, Marr BP, et al. Intravitreal triamcinolone acetonide for acute radiation papillopathy. Retina2006;26:537-544.
52. Chaudhary V, Mao A, Hooper PL, Sheidow TG. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. Ophthalmology2007;114:2183-2189.
53. Gilman AG, Rall TW, Nies AS, Taylor P. The pharmacological basis of therapeutics. Ed 8, rev. New York: Pergamon Press; 1990.
54. Nehmé A, Lobenhofer EK, Stamer WD, Edelman JL. Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics2009;2:58-68.
55. Edelman JL. Differentiating intraocular glucocorticoids. Ophthalmologica2010;224(suppl 1):25-30.
56. Hardman J, Limbird L, Goodman A. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Chicago, IL: McGraw-Hill; 2001.
57. Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol2004;138:1046-1048.
58. Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther2004;20:269-275.
59. Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol1992;110(2): 259-266.
60. Gan IM, Ugahary LC, van Dissel JT, van Meurs JC. Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefes Arch Clin Exp Ophthalmol2005;243(11):1186-1189.
61. Ozurdex [package insert]. Irvine, CA: Allergan Inc; 2009.
62. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol2010;128(3):289-296.
63. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol2007;125(3): 309-317.
64. Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol2009;147(6):1048-1054.
65. Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina2009;29(1):46-51.
66. Chang-Lin JE, Attar M, Acheampong A, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci2011;52(1): 80-86.
67. Brumm M, Nguyen QD. Fluocinolone acetonide intravitreal sustained release device—a new addition to the armamentarium of uveitic management. Int J Nanomedicine2007;2(1):55-64.
68. Jaffe GJ, McCallum RM, Branchaud B, et al. Long-term follow-up results of a pilot trial of fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology2005;112:1192-1198.
69. Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol2007;125:1478-1485.
70. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118:626-635.
71. Zacharias LC, Lin T, Migon R, et al. Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide. Retina2013;33:522-531.
72. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res2005;80:249-258.
73. Dyer D, Callanan D, Bochow T, et al. Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (triesence [triamcinolone acetonide injectable suspension] 40 mg/ml) for visualization during pars plana vitrectomy. Retina2009;29:38-45.
74. Triesence prescribing information. Available at: http://ecatalog.alcon.com/pi/Triesence:us_en.pdf. Accessed September 8, 2012.
75. TRIVARIS. Prescribing Information. Available at: http://www.allergan.com/assets/pdf/trivaris_pi.pdf. Accessed September 8, 2012.
76. The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 6. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard of care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion. Arch Ophthalmol2009;127;1115-1129.
77. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115:1447-1459.
78. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol1999;27:431-432.
79. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol2003;87:24-27.
80. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging2003;34:386-390.
81. The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion. Arch Ophthalmol2009;127:1101-1114.
82. Kaushik S, Gupta V, Gupta A, Dogra MR, Singh R. Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol2004;137:758-760.
83. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology2010;117:1134-1146.
84. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Twelve-month study results. Ophthalmology2011;118:2453-2460.
85. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol2003;136:791-796.
86. Jonas JB, Kreissig I, Degenring RF. Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol2003;121:1663-1669.
87. Gilles MC, Simpson JM, Billson FA, et al.Safety of intravitreal injection of triamcinolone: results from a clinical trial. Arch Ophthalmol2004;122:336-342.
88. Jonas JB, Kreissig I, Degenring RF. Retinal complications of intravitreal injections of triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol2004;242:184-188.
89. Jonas JB, Kreissig I, Spandau UH, et al.Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol2006;141:579-580.
90. Nelson ML, Tennant MT, Sivaligan A, et al.Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone injection. Retina2003;23:686-691.
91. Wang LC, Yang CM. Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide. Ocul Immunol Inflamm2005;13:295-300.
92. Stepien KE, Eaton AM, Jaffe GJ, et al. Increased incidence of sterile endophthalmitis after intravitreal triamcinolone acetonide in spring 2006. Retina2009;29:207-213.
93. Maia M, Farah ME, Belfort RN, Penha FM, et al. Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol2007;91:1122-1124.
94. Song JH, Hong YT, Kwon OW. Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection. Graefes Arch Clin Exp Ophthalmol2008;246:1775-1778.
95. Kocabora MS, Durmaz S, Kandemir N. Exacerbation of central serous chorioretinopathy following intravitreal triamcinolone injection. Graefes Arch Clin Exp Ophthalmol2008;246:1783-1786.
96. Kahook MY, Noecker RJ, Abdelghani WM, Schuman JS. Filtering bleb rupture after intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging2008;39:232-233.
97. Sarraf D, Vyas N, Jain A, et al. Triamcinolone-associated crystalline maculopathy. Arch Ophthalmol2010;128:685-690.
98. Pearson A, Levy B, and the Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabeic macular edema: 2 year results of a multicenter clinical trial. Invest Ophthalmol Vis Sci2005;46:E-Abstract 1795.
99. Yeh WS, Haller JA, Lanzetta P, et al. Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology2012;119:1190-1198.
100. Kuppermann BD, Chou C, Weinberg D, Whitcup SM, Haller JA, Blumenkranz MS. Intravitreous dexamethasone effects on different patterns of diabetic macular edema. Arch Ophthalmol2010;128(5):642-643.
101. Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina2011;31(5):915-923.
102. Schlaegel TF Jr, Wilson FM. Accidental intraocular injection of depot corticosteroids. Trans Am Acad Ophthalmol Otolaryngol. 1978;78:847.
103. Yeung CK, Chan KP, Chiang SW, Pang CP, Lam DS. The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci2003;44:5293-5300.
104. Shaikh S, Ho S, Engelmann LA, Klemann SW. Cell viability effects of triamcinolone acetonide and preservative vehicle formulations Br J Ophthalmol2006;90:233-236.
105. Narayanan R, Mungkal JK, Kenney MC, Seigel GM, Kuppermann BD. Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest Ophthalmol Vis Sci2006;47:722-728.
106. Oh J, Jung YS, Kim GS, Oh IK, Rho B, Huh K. The effect of short-term exposure of triamcinolone acetonide on fibroblasts and retinal pigment epithelial cells. Acta Ophthalmol Scand2007:85:786-790.
107. Chung H, Hwang JJ, Koh JY, Kim J, Yoon YH. Triamcinolone acetonide-mediated oxidative injury in retinal cell culture: comparison with dexamethasone. Invest Ophthalmol Vis Sci2007;48:5742-5749.
108. Zacharias LC, Estrago-Franco MF, et al. The effects of commercially available preservative-free FDA-approved triamcinolone (Triesence) on retinal cells in culture. J Ocul Pharmacol Ther2011;27(2):143-150.
109. Sharma A, Pirouzmanesh A, Patil J, et al. Evaluation of the toxicity of triamcinolone acetonide and dexamethasone sodium phosphate on human lens epithelial cells (HLE B-3). J Ocul Pharmacol Ther2011;27(3):265-271.
110. Kuppermann BD, Patil AJ, Sharma A, et al. Effects of triamcinolone acetonide on human trabecular meshwork cells in vitro. Invest Ophthalmol Vis Sci2008;49:E-Abstract 1614.
111. Lang Y, Zemel E, Miller B, Perlman I. Retinal toxicity of intravitreal Kenalog in albino rabbits. Retina2007;27: 778-788.
112. Kai W, Yanrong J, Xiaoxin L. Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Graefes Arch Clin Exp Ophthalmol2006;244:1152-1159.
113. Macky T, Helmy D, Shazly NE. Retinal toxicity of triamcinolone’s vehicle (benzyl alcohol): an electrophysiological and electron microscopic study. Graefes Clin Exp Ophthalmol2007;245:817-824.
114. Szurman P, Sierra A, Kaczmarek R, et al. Different biocompatibility of crystalline triamcinolone on retinal cells in vitro and in vivo. Exp Eye Res2007;85:44-53.
115. Szurman P, Kaczmarek R, Spitzer MS, et al. Differential toxic effect of dissolved TA and its crystalline crystals on cultured human retinal pigment epithelium (ARPE19) cells. Exp Eye Res2006;83:584-592.
116. Lüke M, Januschowski K, Beutel J, et al. The effects of triamcinolone crystals on retinal function in a model of isolated perfused vertebrate retina. Exp Eye Res2008;87:22-29.
117. Dierks D, Lei B, Zhang K, Hainsworth DP. Electroretinographic effects of an intravitreal injection of triamcinolone in rabbit retina. Arch Ophthalmol2005;123:1563-1569.
118. Kim H, Csaky C, Gravlin L, et al. Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina2006;26:523-530.
119. Albini TA, Abd-El-Barr MM, Carvounis PE, et al. Long-term retinal toxicity of intravitreal commercially available preserved triamcinolone acetonide (Kenalog) in rabbit eyes. Invest Ophthalmol Vis Sci2007;48:390-395.
120. Zenghyu S, Fang W, Ying F. Vehicle used for triamcinolone is toxic to ocular tissues of the pigmented rabbit. Cur Eye Res2009;34:769-776.
121. Maia M, Penha FM, Farah ME, et al. Subretinal injection of preservative-free triamcinolone acetonide and supernatant vehicle in rabbits: an electron microscopy study. Graefes Arch Clin Exp Ophthalmol2008;246:379-388.
122. Charcoal stripped fetal bovine serum. Manufacturer information. Available at: http://www.lifetechnologies.com/br/en/home/life-science/cell-culture/mammalian-cell-culture/fbs/specialty-serum/charcoal-stripped-fbs.html on December 26, 2013.
123. Chang YS, Wu CL, Tseng SH, Kuo PY, Tseng SY. Cytotoxicity of triamcinolone acetonide on human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci2007;48:2792-2798.
124. Seigel GM. Establishment of an E1A-immortalized retinal cell culture. In Vitro Cell Dev Biol Anim1996;32(2):66-68.
125. Seigel GM, Sun W, Wang J, et al. Neuronal gene expression and function in the growth-stimulated R28 retinal precursor cell line. Curr Eye Res2004;28(4): 257-269.
126. Sun W, Seigel GM, Salvi RJ. Retinal precursor cells express functional ionotropic glutamate and GABA receptors. Neuroreport2002;13:2421-2424.
127. Narayanan R, Kenney MC, Kamjoo S, et al. Toxicity of indocyanine green (ICG) in combination with light on retinal pigment epithelial cells and neurosensory retinal cells. Curr Eye Res2005;30(6):471-478.
128. Narayanan R, Kenney MC, Kamjoo S, et al. Trypan blue: effect on retinal pigment epithelial and neurosensory retinal cells. Invest Ophthalmol Vis Sci2005; 46(1): 304-309.
129. Cellerino A, Bahr M, Isenmann S. Apoptosis in the developing visual system. Cell Tissue Res2000;301:53-69.
130. Spitzer M, Mlynczak T, Schultheiss M, et al. Preservative-free triamcinolone injectable suspension versus “traditional” triamcinolone preparations: Impact of aggregate size on retinal biocompatibility. Retina2011; 31(10):2050-2057.
131. He S, Wang HM, Ye J, Ogden TE, Ryan SJ, Hinton DR. Dexamethasone induced proliferation of cultured retinal pigment epithelial cells. Curr Eye Res1994;13(4):257-261.
132. Shimada H, Matsui M. Effects of intravitreal injection on rabbit eye. Nippon Ganka Gakkai Zasshi1989;93:501-510.
133. Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol1986;101:190-195.
134. Chen V, Bartov E, Blumenthal M. Inadvertent intravitreal injection of betamethasone. Metab Pediatr Syst Ophthalmol1988;11:61-62.
135. Piccolino FC, Pandolfo A, Polizzi A, Eandi C, Ventre L. Retinal toxicity from accidental intraocular injection of depomedrol. Retina2002;22(1):117-119.
136. Wilson DR, Kimble JA, Witherspoon CD, Morris R. Retinal toxicity from accidental intraocular injection of a depot corticosteroid: a case report. Ann Ophthalmol Glaucoma1994;26:126-130.
137. Zinn KM. Iatrogenic intraocular injection of depot corticosteroid and its surgical removal using the pars plana approach. Ophthalmology1981;88:13-17.
138. Pesce AJ, McKean DL. Toxic susceptibilities in the newborn with special consideration of polysorbate toxicity. Ann Clin Lab Sci1989;19:70-73.
139. Levy M, Dupuis LL. Parenteral nutrition hypersensitivity. J Parenter Enteral Nutr1990;14:213-215.
140. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet1995;345:1312-1313.
141. McGee DH, Dembinska O, Gruebbel MM. Evaluation of triamciolone acetonide following intravitreal injection in New Zealand white rabbits. Int J Toxicol2005;24:419-425.
142. Walter P, Luck C, Sickel W. Antibiotics and light responses in superfused bovine retina. Cell Mol Neurobiol1999;19:87-92.
143. Morrison VL, Koh HJ, Cheng L, Bessho K, Davidson MC, Freeman W. Intravitreal toxicity of the kenalog vehicle (Benzyl Alcohol) in rabbits. Retina2006;26:339-344.
144. Garcia-Arumi J, Boixadera A, Giralt J, et al. Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. Br J Ophthalmol2005;89:1112-1114.
145. Petersen S, Steiniger F, Fischer D, Fahr A, Bunjes H. The physical state of lipid nanoparticles influences their effect on in vitro cell viability. Eur J Biopharm2011;79:150-161.